Komori
Earnings4552JCR Pharmaceuticals Co.,Ltd.Pharmaceuticals

(Correction) Partial correction to the "Summary of Financial Results for the Fiscal Year Ended March 2025 (Japanese GAAP) (Consolidated)"

The Summary of Financial Results for the fiscal year ended March 2025 was corrected due to errors in part of the disclosure. The text provided does not identify the corrected tables or items, or the figures before and after correction.

Worth reading
100Important
Scored from 1 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure13 May 2025

Summary of Financial Results for the Fiscal Year Ended March 2025 [Japanese GAAP] (Consolidated)

Open the original document
365 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-05-13
Reason for correction

The Summary of Financial Results for the Fiscal Year Ended March 2025 [Japanese GAAP] (Consolidated) contained errors in part of its disclosure, and has therefore been corrected.

What was corrected and how
ItemDetails
Disclosure subject to correctionSummary of Financial Results for the Fiscal Year Ended March 2025 [Japanese GAAP] (Consolidated)
Original disclosure date13 May 2025
Reason for correctionThe Summary of Financial Results for the Fiscal Year Ended March 2025 [Japanese GAAP] (Consolidated) contained errors in part of its disclosure, and has therefore been corrected.
Items this document does not state (3)
Location of correctionDetails of correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

There were errors in part of the Summary of Financial Results for the fiscal year ended March 2025.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial correction to the "Summary of Financial Results for the Fiscal Year Ended March 2025 (Japanese GAAP) (Consolidated)" | JCR Pharmaceuticals Co.,Ltd. (4552) timely disclosure | Komori